Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?

Current opinion in hematology - 1 Mar 2009

Dombret Hervé, Preudhomme Claude, Boissel Nicolas

Abstract excerpt

PURPOSE OF REVIEW: Core binding factor acute myeloid leukemia (CBF-AML) corresponds to two distinct subtypes of AML characterized by recurrent favorable chromosome translocations, namely t(8;21) and inv(16)/t(16;16). Given the relatively good outcome of patients with CBF-AML, when treated with intensive chemotherapy including high-dose cytarabine, they are generally not considered as candidates for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Core Binding Factors
Share to Cytarabine
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Expression Profiling

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Prognosis

Source

Identifiers

PMID: 19468270
DOI: 10.1097/MOH.0b013e3283257b18

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?PMID 19468270Read ↗

Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?Semantic proximity Read ↗

Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities.Semantic proximity Read ↗

Core‐binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapySemantic proximity Read ↗

Complex karyotype, older age, and reduced first‐line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long‐term follow‐upSemantic proximity Read ↗

Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia.Semantic proximity Read ↗

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.Semantic proximity Read ↗

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML IntergroupSemantic proximity Read ↗

Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual diseaseSemantic proximity Read ↗

Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemiaSemantic proximity Read ↗

Core-Binding Factor Acute Myeloid LeukemiaSemantic proximity Read ↗

Core Binding Factor AML Beyond Favorable Risk: Molecular Heterogeneity, MRD Dynamics, and Implications for Clinical Decision-MakingSemantic proximity Read ↗

Genetic abnormalities in core binding factor acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.